AlphaYou
Overview
Smart money at a glance
Filings to Oct 2, 2026Net selling: insiders sold $7.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$7.2M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Mar 31, 2026
- 0 added, 1 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- 3 awardsAwards on record
Key stats
Fundamentals Oct 2- Open
- $34.90
- 52-wk high
- $44.28
- High
- $36.03
- 52-wk low
- $17.72
- Low
- $34.14
- Prev close
- $34.88
- Mkt cap
- $1.09B
- Volume
- 639.6K
- Beta
- 1.00
- P/S
- 3.0x
- P/B
- 2.3x
- Profit margin
- -5.4%
- Op margin
- -3.0%
- ROE
- -4.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CSTL filings
Are insiders buying or selling Castle Biosciences Inc (CSTL) stock?
Net selling: insiders sold $7.2M and bought $0 of CSTL stock on the open market in the 90 days to Oct 2, 2026, according to SEC Form 4 filings. $5.6M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Maetzold, Derek J (Pres. & Chief Exec. Officer), who sold $3.9M. The latest filing was on Oct 1, 2026.
Which members of Congress have traded CSTL recently?
None. No member of Congress disclosed a CSTL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CSTL smart-money data?
This summary uses filings available on Oct 2, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (1)
- BO
Bank of America
$8.6M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CSTL right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 84.1% above what analysts expected.
Earnings per share
-$0.44 expected
Reports Nov 2, 2026, in 31 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $83.0M | $87.0M | $83.7M | $103.5M |
| Cost of what it sold | $18.7M | $18.3M | $20.5M | $23.7M |
| Gross profit | $64.3M | $68.7M | $63.1M | $79.8M |
| What it spent | ||||
| Research and development | $13.0M | $13.5M | $14.4M | $14.5M |
| Sales and admin | $23.1M | $23.3M | $23.9M | $25.2M |
| Other operating costs | $35.1M | $35.7M | $43.3M | $43.2M |
| Total operating expenses | $71.1M | $72.5M | $81.6M | $82.9M |
| What was left | ||||
| Operating profit | -$6.8M | -$3.8M | -$18.4M | -$3.1M |
| Interest on debt | $24.0K | $24.0K | $134.0K | $193.0K |
| Profit before tax | -$386.0K | -$2.7M | -$14.4M | -$1.7M |
| Tax | $115.0K | -$382.0K | $109.0K | $370.0K |
| Net profit | -$501.0K | -$2.3M | -$14.5M | -$2.1M |
| EBITDA | $3.5M | $1.1M | -$10.3M | $2.6M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace